rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Ben R. Taylor

Chief Financial Officer

Company insider

Files Form 4 as: Chief Financial Officer, Recursion Pharmaceuticals; President, CFO, Tyme Technologies.

Every Form 4 they filed

In numbers

Trades disclosed
50
Buys
1
Sells
3
Bought
$10K
Sold
$226K
Companies
2
Companies where not an officer
0
First trade
22 Nov 2017
Last trade
15 Sep 2026
Last filed
16 Sep 2026

Companies traded

Where they are an officer
RXRX Recursion PharmaceuticalsOfficer · Biotechnology · last 15 Sep 20260 buys · 3 sells
Tyme TechnologiesOfficer · last 7 May 20201 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
10Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
15 Sep 2026filed 16 Sep 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$18K5,396 at $3.41filing
15 Sep 2026filed 16 Sep 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$18K5,396 at $3.41filing
17 Aug 2026filed 18 Aug 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$79K25,018 at $3.16filing
17 Aug 2026filed 18 Aug 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$79K25,018 at $3.16filing
15 Jun 2026filed 17 Jun 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$17K5,396 at $3.15filing
15 Jun 2026filed 17 Jun 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$17K5,396 at $3.15filing
15 May 2026filed 19 May 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$76K25,018 at $3.04filing
15 May 2026filed 19 May 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$76K25,018 at $3.04filing
6 Apr 2026filed 8 Apr 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$149K48,028 at $3.11filing
6 Apr 2026filed 8 Apr 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$149K48,028 at $3.11filing
17 Mar 2026filed 18 Mar 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Sold$27K7,956 at $3.39filing
17 Mar 2026filed 18 Mar 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Sold$27K7,956 at $3.39filing
16 Mar 2026filed 18 Mar 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$24K7,075 at $3.42filing
16 Mar 2026filed 18 Mar 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$24K7,075 at $3.42filing
18 Feb 2026filed 19 Feb 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Sold$41K13,426 at $3.08filing
18 Feb 2026filed 19 Feb 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Sold$41K13,426 at $3.08filing
17 Feb 2026filed 19 Feb 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$42K11,908 at $3.49filing
17 Feb 2026filed 19 Feb 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code F$42K11,908 at $3.49filing
6 Feb 2026filed 10 Feb 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—446,279 at $0.00filing
6 Feb 2026filed 10 Feb 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—24,254 at $0.00filing

Sectors

Health Care3
Not placed1

Buys in green, sells in red, by the company’s sector.

Related people

Blake BorgesonDirector · Director at Recursion Pharmaceuticals, filing Form 4 there in the last year
Robert HershbergDirector · Director at Recursion Pharmaceuticals, filing Form 4 there in the last year
Dean Y. LiDirector · Director at Recursion Pharmaceuticals, filing Form 4 there in the last year
Zavain DarDirector · Director at Recursion Pharmaceuticals, filing Form 4 there in the last year
Najat KhanCEO and President · CEO and President at Recursion Pharmaceuticals, filing Form 4 there in the last year